Grants and Contributions:
Title:
Developing immunomodulation capabilities for NanoDenrix Phytoglycogen
Agreement Number:
907205
Agreement Value:
$200,000.00
Agreement Date:
Apr 1, 2018 - Feb 28, 2019
Description:
Mirexus’ proprietary material - trademarked NanoDendrix™ (NaD) is a platform for the development of multiple pharmaceutical applications of safe and natural nanotechnology. Early discovery research has shown selected derivatives can be modified to regulate (either enhance or inhibit) the interferon mediated innate immune response. This further can be used to enable the enhanced production of viruses grown in cell cultures…a potentially disruptive advance in the virus production industry.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Guelph, Ontario, CA N1G 3M5
Reference Number:
172-2018-2019-Q1-907205
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
814184156
Recipient Type:
For-profit organization
Recipient's Legal Name:
Mirexus Biotechnologies Inc.
Federal Riding Name:
Guelph
Federal Riding Number:
35032
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171